Jeffrey M. Soinski
joining thank Thank you and all afternoon, you, us. Matt. for Good
infections our procedural and shortages, healthcare and in COVID-XX challenging volume. March we The As the procedure-focused facility first many affected environment hospital access Omicron reduced medical limited discussed surge hospital the quarter and companies staffing device from XXXX. variant and a of that experienced on call,
that As lower the during first-quarter what is trends volume seen a a compared happy quarter. trends commercial surge our increase we to imaging full improve activity in console, revenue an also customer result in year-ago quarters. new second in We've procedural typically recently with seen launched March the period, We've associated seasonal and Lightbox decreased report April. from in to to availability these starting volume X prior of and are continue the revenue which in improvement into
treat or supports the OCT can of system where Our including of Lumivascular total best-in-class treatment effectively treatment with combining of to their therapeutic challenging, limb patients. imaging are highly system, safely in-stent peripheral ischemia, proprietary artery by PAD. With intravascular and disease of effective cases Avinger's the the severe primarily and in more order outcomes image-guided most PAD We challenging PAD. occlusions, the focus real-time to preserve and catheters be the for empowered cases chronic critical restenosis, physicians form limbs on proprietary market these patient hospital lives
identified we've through on year, focus increasing key platform three of and As market we our drivers remainder expanding business. case of volume the our growth for penetration this
existing in full helping the already X our of installation Lightbox positive base our with without and new highly has receiving January strategies. support console The successful with exciting, portable X is designed Console easy with in the expanding an is user ability customized our transform procedural system April. reviews receiving laser hospitals in incorporates software to and effectively Next We potential our imaging believe user expanded Imaging setup our for accounts imaging, X and for existing after designed the a system clearance open Lightbox a an more ease connection high-definition for first redesigned field availability to computing by launch state the new quarter, First, launch intuitive solid X a business interface expand Lightbox model platform, FDA efficiency a we to of limited response compact, team The in with cath OCT lab. from and the this of Generation in powerful advanced users completing The console. monitors and Lightbox permanent use. commercial
limited the vessel enhanced injury deploy to support of easily on a avoid During us option strategy and XX size wheeled upgrade productivity can less U.S. team use single fits enable with side We efficiently the stand which the exciting to XX Pantheris of clinical a is facilitates and CTO in high-definition available an catheters X platform. out X demonstrations morphology case into But new onsite up identification existing of be Users this our pace new as be utilization minutes. permanent sites, a in Lightbox by accounts by account clinical across new to multiple the disease to increase the Lightbox were option the this acquisition. new physicians carry for the effectively believe can capital to and set TigerEye sales will which Lightbox a limited The configurations validated and hard arterial new territories accounts. team strategy facility phase, our target a and roller disease the throughout a portable extremely The We've sites. wall treatment. Lightbox support also weighs suitcase, highly X portable X accelerate and for of than d sites during to to launch evaluations and rolled of physicians new hospital on our sales structures. and and portable into and pounds, sale atherectomy the Avinger's, in new mobile XX portable at impressed crossing, the wall Allowing imaging
the designed drive line initiative development X, of combination products our catheter product broaden our the for expand Lightbox The is second to In two appeal of growth peripheral new technology, our growth. portfolio. base our exciting new new with and user these extensions are
in spinning tough shaft for is our catheter new has and across plaque extension guided response consistent image environment, development design crossing caps an for CTO in interpretation This TigerEye tip new challenging an catheter facilitate and to and pushability our image three-marker a outer advanced calcium, of crossing a platform. platform. imaging torque in product first system The CTO integrated
We patient to expect CTO availability and this to to is submit platform, year. a X-XX in addressable the capabilities of half commercial mid-year in market the this advanced k application for anticipated device the population. a challenging products utility clearance new expected expand FDA in second our By adding with
image-guided This new in approach where extension devices. procedures physicians device majority an catheter of for PAD is family a and and including streamlined of arteries, the treatment emphasizes performed new are second vessels, The development the of popliteal our for SFA larger of today. capabilities our expands Pantheris atherectomy the
as management plaque need enhancements. without rotational LV management a operate vessels for our are also complement catheter, designed calling new Pantheris system LV tissue for small Pantheris those and and packing, a at modified plaque. plaque other efficient for which a for for speed treatment the balloon in adds well higher We proprietary this Pantheris guidewire and vessels, challenging catheter is is larger control to acquisition design to utilizes successful rotational for as knee. below especially Pantheris several vessel as SV of LV a the large designed the
more the in commercial a file We atherectomy XXX XXXX, this to new k market We anticipated portfolio of in and advancements streamlined XXXX. half with with an the of LV the largest product device our application for supporting in availability by bringing first believe will second device a segment. significant expect Pantheris easier expand to half penetration to atherectomy use procedure
third disease reimbursement expansion the initiative market, large provides the challenges opportunity market. compelling Avinger clinical advantages leverage We due the believe addressable the approach. our The into to opportunity coronary to and platform market our artery is unique potential transformational its image-guided and vast growth coronary in to profile, of Lumivascular a existing the value proprietary for address
a both for Our steep platform, advances percutaneous new these occlusions a patients. crossing including the imaging media first of an crossing medical addressable incorporates a number Existing of have large is We require CTOs by Avinger exposure a the safe, X market. deliver extended chronic time leveraging proprietary opportunity in high our is PCI this of crossing with burden, arteries. solution require development or Lightbox procedures treating devices. into the that By PCI are catheter the also radiation total we've an reliable, foray multiple system made centers our the coronary procedure. specialized to use into market our expensive, and OCT in transform results fluoroscopy, with guidance across CTO contrast in uncertain and performed believe and expanding new, to team demanding Approximately procedures today CTO year, U.S. which complex, highly XX,XXX what solutions health the under creating can These risks in we coronary device for a and OCT-guided interested console, hospital complex, patient-oriented the x-ray curve, technique are procedures patient. of learning CTO the increasing each and
of XX% that procedure. image In treatment exposure guided estimates and would reduce U.S. a market XXX,XXX crossing contrast up immediately for percutaneous CTO our FDA of highly make to crossing invasive has system, coronary diagnostic approach in annually, coronary performed target $XX,XXX procedures of would an more device artery the accessible or An grafting currently addition, with bypass burden This to during upon image-guided U.S. capabilities reimbursement to highly CABG are than ercutaneous per and also more it's estimated of procedure. the provides radiation P with the clearance. the attractive to in exciting coronary reimbursement procedures these CTOs. related which physicians access CTO $XX,XXX x-ray
and arteries. crossing qualify an image-guided with imaging compelling reimbursement support opportunity resolution fewer scenario the with the catheter OCT-guided believe designed reimbursement devices, provides combined will measurement efficiency in the OCT diagnostic We need with anticipate for attractive economic that value catheters a very proposition. we for addition, coronary In diagnostic capabilities for that for existing high an
optical are profile and capability focused approach wall. is physicians to peripheral regulatory We our while submission incorporate coronary trial. the measurement and to with and to that on physicians IDE cross precise avoiding suited antegrade for first a real-time catheter stents the steerability allow XXX outcomes. facilitate Avinger's pathway to OCT device will to coronary placement, anticipate balloons to U.S. catheters, or efficiently data designs prior new injury by which low for combine critical Similar Our safely development properly an CTO vessel CTOs supported ideally an guidance device for precise control from size be a coronary clinical this k to efforts
this goal end of XXXX. position be to study by the initiate a in Our to is
Clinical PAD. In The we our at insight to of benefits in positive Lumivascular the anticipate that investigators the clinical basis the the body successful will submission the of Pantheris of to fourth data addition presented treatment the of the this the insight for IDE trial, VIVA ISR. our continue treatment year. to to to study from restenosis build indication clinical our provided Clinical data efforts, for evaluating We XXXX. was the or from product full of XXX Conference this quarter the of approach for evidence development in-stent publication support expand treatment the for k study dataset include submit highly our physician in Pantheris from ISR,
in from at -- data post-procedure. up the intervals enroll to patients year up XX clinical addition, evaluated one study patients we with to to In expect
centers patients today the severe challenging they are the most at results seeing ischemia key enrolling enrolling physician excited patients form patient the quarter. or in of PAD. currently to investigators from Most enrolled Germany at are critical two are in this in And expect leader clinical early opinion suffer sites CLI, We U.S. patients population. limb clinical begin two leading and this about
XXXX data to conferences expect We end presentation of by complete at this with year. the available for enrollment clinical interim
volume encouraged As case by as are second the in quarter seeing we forward market we're conditions XXXX, we look in increasing improve. the
new to the We our of commercial expand X market this Lightbox console are accelerate excited penetration account of about and for new and launch new recent our acquisition. pace potential the
new PAD the two appeal products product platform to will usage We broaden XXX and for of portfolio, innovative pace which occasions. believe are in k our on we create new file our submissions
evidence effort of treatment clinical continue outstanding into our the first-ever coronary for markets clinical CTO support through a programs. products to our We device the the patient R&D we're and of focused deliver CAD. for highly entry preparing through body document outcomes crossing to image-guided build the study And of in
important drivers we and of All the company our for stockholders. value which believe build will growth for be
has medical to team. a our many our this XXXX, in Before end as We resigned recently management Mark appreciate catheters We company him the the the to wish of Marks And next-generation an the our effective We've well fill his position, to I I'd us the future. in this business of helping joining turn and over to Q&A. development announced like phase contributions the week you I'll search next the the an the new that of CFO our pursue PAD us with update a to call I'd Weinswig through return our we transform and Mark, and since introduction comment Officer and the of Chief like on X change to to outside industry. platform. forward moves look Mark Lightbox providing financials career. process launch Financial cover as point, to to for then ask to Mark? At initiated opportunity
